Maxime Verhoeven

119 Effectiveness and safety of treat-to-target strategies over 5 years Supplementary Table S1 Characteristics of patients included and not included in the post-trial follow-up, at start of U-Act-Early and at last visit of U-Act-Early. At start of U-Act-Early At last visit of U-Act-Early Included in follow- up n=226 Not included in follow-up n=91 P-value Included in follow-up n=226 Not included in follow-up n=91 P-value Female, n (%) 156 (69) 56 (62) 0.20 DAS28, mean (SD) 1.94 (0.99) 3.61 (1.99) <0.01 RF +, n (%) 166 (74) 63 (69) 0.38 Remission, n (%) 180 (81) 43 (19) <0.01 Anti CCP +, n (%) 161 (74) 62 (68) 0.51 HAQ, mean (SD) 0.59 (0.56) 0.80 (0.66) 0.01 RF- and/or anti-CCP+, n (%) 181 (80) 68 (75) 0.26 SvdH Score, median (IQR) 0 (0 - 3) 0 (0 - 5) 0.98 Caucasian, n (%) 219 (97) 85 (93) 0.02 Safety, n (%) - AE - SAE 224 (99) 27 (12) 88 (97) 22 (24) 0.27 <0.01 Age (years), mean (SD) 54.3 (11.9) 51.1 (14.8) 0.09 Smoking status, n (%) - Never smoked - Quit smoking - Current smoking 91(40) 70 (31) 65 (29) 38 (42) 28 (31) 25 (27) 0.96 Follow-up time in days, median (IQR) 104 (103 – 106) 55 (32 – 92) <0.01 Symptom duration (days), median (IQR) 26 (18 – 43) 27 (16 – 46) 0.83 Follow-up time in days, median (IQR) 104 (103 – 106) 55 (32 – 92) <0.01 DAS28, mean (SD) 5.2 (1.1) 5.4 (1.1) 0.25 HAQ, median (IQR) 1.1 (0.6 – 1.6) 1.1 (0.8 – 1.5) 0.98 Follow-up time in days, median (IQR) 104 (103 – 106) 55 (32 – 92) <0.01 SvdH score, median (IQR) 0 (0 – 1) 0 (0 – 1) 0.25 RF= rheumatoid factor; += positive; anti-CCP= anti-cyclic citrullinated peptide antibodies; SD= standard deviation; IQR= interquartile range; DAS28= disease activity score assessing 28 joints; HAQ= health assessment questionnaire; SvdH= Sharp van der Heijde score; AE= adverse event; SAE= serious adverse event. 6